Corneal neovascularization: Molecular events and therapeutic options

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 3, 2009, Pages 221-231

  Shakiba, Yadollah ^a,b   Mansouri, Kamran ^b   Arshadi, Delnia ^b   Rezaei, Nima ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cornea; Inflammation; MMP; Neovascularization; VEGF

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CELECOXIB; CORTICOSTEROID; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KETOPROFEN; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; COLORECTAL CANCER; CORNEA NEOVASCULARIZATION; DIATHERMY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; HERPES SIMPLEX KERATITIS; HUMAN; LASER COAGULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PATENT; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; DRUG DESIGN; ENDOTHELIUM, CORNEAL; HUMANS; INFLAMMATION; PATENTS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350766658     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309789257450     Document Type: Review

References (208)

1. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002; 22(1): 13-46.
2. Gipson IK, Inatomi T. Cellular origin of mucins of the ocular surface tear film. Adv Exp Med Biol 1998; 438: 221-227.
3. Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68(4): 799-801.
4. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9(6): 685-693.
5. Colby KA, Adamis AP. Prevalence of corneal neovascularization in a general eye service population (Abstract). Invest Ophthalmol Vis Sci 1996; 37: S593.
6. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007; 26(1): 1-37.
7. West SK. Trachoma: New assault on an ancient disease. Prog Retin Eye Res 2004; 23(4): 381-401.
8. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiologic review. Surv Ophthalmol 1998; 43(3): 245-269.
9. Zheng M, Schwarz MA, Lee S, et al. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 2001; 159(3): 1021-1029.
10. Kremer I, Cohen EJ, Eagle RC Jr, et al. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis. CLAO J 1994; 20(1): 45-48.
11. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12(4): 242-249.
12. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995; 14(6): 604-609.
13. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27(10): 1195-1199.
14. Rozenman Y, Donnenfeld ED, Cohen EJ, et al. Contact lens-related deep stromal neovascularization. Am J Ophthalmol 1989; 107(1): 27-32.
15. Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J 2002; 28(1): 12-27.
16. Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGFC and VEGF-D. Int J Biochem Cell Biol 2001; 33(4): 421-426.
17. Lyttle DJ, Fraser KM, Fleming SB, et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994; 68(1): 84-92.
18. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93(8): 1493-1495.
19. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267(36): 26031-26037.
20. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266(18): 11947-11954.
21. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-865.
22. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 2006; 312(5): 527-537.
23. Senger DR, Connolly DT, Van de Water L, et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50(6): 1774-1778.
24. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001; 276(52): 49289-49298.
25. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-Adependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20(11): 2768-2778.
26. Singh N, Amin S, Richter E, et al. Flt- 1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005; 46(5): 1647-1652.
27. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor VEGF and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004; 82(5): 557-563.
28. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 2003; 44(1): 117-123.
29. Zhou LH, Xing YQ, Chen CL, et al. Antisense vascular endothelial growth factor suppressed corneal neovascularization in rats. Zhonghua Yan Ke Za Zhi 2006; 42(5): 426-430.
30. Murata M, Takanami T, Shimizu S, et al. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res 2006; 31(2): 171-180.
31. Lai CM, Spilsbury K, Brankov M, et al. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002; 75(6): 625-634.
32. Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165(6): 2177-2185.
33. Chen J, Liu W, Liu Z, et al. Expression of vascular endothelial growth factor and its receptors (FLT-1) in morbid human corneas and investigation of its clinic importance. Yan Ke Xue Bao 2002; 18(4): 203-207.
34. Seta F, Patil K, Bellner L, et al. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat 2007; 84(3-4): 116-127.
35. Phillips GD, Stone AM, Jones BD, et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994; 8(6): 961-965.
36. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001; 75(20): 9828-9835.
37. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39(1): 18-22.
38. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008; 27(1): 70-73.
39. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (avastin) for corneal neovascularization-corneal light shield soaked application. Cornea 2009; 28(2): 246-247.
40. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008; 33(1): 23-28.
41. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27(10): 1195-1199.
42. Han YS, Lee JE, Jung JW, et al. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247(4): 541-548.
43. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF-neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50(5): 2095-2102.
44. Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008; 27(3): 357-362.
45. Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009; 50(4): 1659-1665.
46. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27(3): 349-352.
47. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27(2): 142-147.
48. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27(9): 992-995.
49. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115(6): e33-38.
50. Shakiba Y, Arshadi D. Inhibition of corneal neovascularization with new tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors: Sunitinib malate and Sorafenib. Irn J Med Hypotheses Ideas 2007; 1:1
51. Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph) angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008; 49(5): 1836-1842.
52. Kimihiko, F., Tatsuro, I., Tadahisa, K., Yukio, S.: EP0811711A1 (2006).
53. Rosenblum, M.G., Campochiaro, P. A.: US2007025957A1 (2007).
54. Adamis, A. P., Guyer, D. R., Modi, M. W.: US2006293270A1 (2006).
55. Hayashi N, Nakayasu K, Okisaka S. Immunohistochemical localization of acidic and basic fibroblast growth factor through corneal neovascularization in vivo and in vitro. Nippon Ganka Gakkai Zasshi 1996; 100: 587-591.
56. Gan L, Fagerholm P, Palmblad J. Expression of basic fibroblast growth factor in rabbit corneal alkali wounds in the presence and absence of granulocytes. Acta Ophthalmol Scand 2005; 83(3): 374-378.
57. Saghizadeh M, Chwa M, Aoki A, et al. Altered expression of growth factors and cytokines in keratoconus, bullous keratopathy and diabetic human corneas. Exp Eye Res 2001; 73(2): 179-189.
58. Adamis AP, Meklir B, Joyce NC. in situ Injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol 1991; 139: 961-967.
59. Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc 2007; 2(10): 2545-2550.
60. Kojima T, Chang JH, Azar DT. Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol 2007; 170(2): 764-773.
61. Xu X, Weinstein M, Li C, et al. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development 1998; 125(4): 753-765.
62. Deng CX, Wynshaw-Boris A, Shen MM, et al. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 1994; 8: 3045-3057.
63. Soubrane G, Jerdan J, Karpouzas I, et al. Binding of basic fibroblast growth factor to abnormal and neovascular rabbit cornea. Invest Opthalmol Vis Sci 1990; 31: 323-333.
64. Kurokawa M, Doctrow SR, Klagsbrun M. Neutralizing antibodies inhibit the binding of basic fibroblast growth factor to its receptor but not to heparin. J Biol Chem 1989; 264(13): 7686-7691.
65. Xiang, J., Deng, N., Li, H.: CN1560082A (2004).
66. Yoshitake, Y., Nishikawa, K., Osawa, M, Asano, M., Koda, A., Suzuki, H.: JP11049701A (1997)
67. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 928: 827-839.
68. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 217: 1104-1117.
69. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49(1-3): 117-137.
70. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001; 5082: 187-190.
71. Zhang H, Li C, Baciu PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2002; 434: 955-962.
72. Rigal-Sastourne JC, Tixier JM, Renard JP, et al. Corneal burns and matrix metalloproteinases MMP-2 and -9: The effects of human amniotic membrane transplantation. J Fr Ophtalmol 2002; 257: 685-693.
73. Ma DH, Chen JK, Kim WS, et al. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. Ophthalmic Res 2001; 336: 353-362.
74. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 704: 419-428.
75. Samolov B, Steen B, Seregard S, et al. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005; 802: 159-166.
76. Berglin L, Sarman S, van der Ploeg I, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci 2003; 441: 403-408.
77. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci 1998; 39: 913-921.
78. Sakimoto T, Shoji J, Yamada A, et al. Upregulation of matrix metalloproteinase in tear fluid of patients with recurrent corneal erosion. Jpn J Ophthalmol 2007; 51(5): 343-346.
79. Swarnakar S, Ganguly K, Kundu P, et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 2005; 280(10): 9409-9415.
80. Gonzales RP, D-Soares FS, Farias RF, et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. Biol Pharm Bull 2001; 24: 151-154.
81. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51(2): 672-675.
82. Sucholeiki, I., Gege, C., Gallagher, B, Powers, T., Deng, H., Wu, X., Steeneck, C., Kiely, A., Taveras, A.: US20080021024A1 (2008).
83. Singh N, MacNamara E, Rashid S, et al. Systemic soluble Tie-2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun 2005; 332: 194-199.
84. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003; 100: 5028-5033.
85. Oike Y, Ito Y, Maekawa H, et al. Angiopoietin-related growth factor (AGF) promotes angiogenesis. Blood 2004; 103(10): 3760-3765.
86. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-291.
87. Cao Y, Linden P, Shima D, Browne F, Folkman J. in vivo Angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/ vascular endothelial growth factor. J Clin Invest 1996; 98(11): 2507-2511.
88. Cohen RA, Gebhardt BM, Bazan NG. A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization. Curr Eye Res 1994; 13(2): 139-144.
89. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001; 33(2): 95-102.
90. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; 158(3): 1111-1120.
91. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45: 1117-1124.
92. Nor JE, Mitra RS, Sutorik M, et al. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000; 37: 209-218.
93. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-48.
94. Vande Woude, G. F., Zhang, Y.W.: US20070020234A1 (2007).
95. Zak S, Treven J, Nash N, et al. Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int J Colorectal Dis 2008; 23(3): 297-304.
96. Zhou L, Isenberg JS, Cao Z, et al. Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1. Oncogene 2006; 25: 536-545.
97. Hiscott P, Seitz B, Schlotzer-Schrehardt U, et al. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res 1997; 289(2): 307-310.
98. Kanda S, Shono T, Tomasini-Johansson B, et al. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999; 252(2): 262-272.
99. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory and antiangiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008; 26(4): 1047-1055.
100. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989; 30: 1700-1707.
101. Becerra SP, Sagasti A, Spinella P, et al. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem 1995; 270(43): 25992-25999.
102. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: A potent inhibitor of angiogenesis. Science 1999; 285(5425): 245-248.
103. Notari L, Miller A, Martinez A, et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: Implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 2005; 46(8): 2736-2747.
104. Abe R, Fujita Y, Yamagishi S, et al. Pigment epithelium-derived factor prevents melanoma growth via angiogenesis inhibition. Curr Pharm Des 2008; 14(36): 3802-3809.
105. Iizuka H, Awata T, Osaki M, et al. Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. Biochem Biophys Res Commun 2007; 361(2): 421-426.
106. Bouck N. PEDF: Anti-angiogenic guardian of ocular function. Trends Mol Med 2002; 8(7): 330-334.
107. Meyer C, Notari L, Becerra SP. Mapping the type I collagenbinding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 2002; 277: 45400-45407.
108. Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264-302.
109. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
110. Cao R, Wu HL, Veitonmaki N, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasminmediated proteolysis. Proc Natl Acad Sci USA 1999, 96: 5728-5733.
111. Shin SH, Kim JC, Chang SI, et al. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 2000; 19: 212-217.
112. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
113. Sack RA, Beaton AR, Sathe S. Diurnal variations in angiostatin in human tear fluid: A possible role in prevention of corneal neovascularization. Curr Eye Res 1999; 18: 186-193.
114. Gabison E, Chang JH, Hernandez-Quintela E, et al. Antiangiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004; 78: 579-558.
115. Folkman, J., O'Reilly, M., Cao, Y., Sim, K.: US20090075369A1 (2009).
116. Soff, G., Gately, S.T., Twardowski, P.: US20060099671A1 (2006).
117. O'Reilly, M.S., Folkman, M. J., Cao, Y.: US20040023877A1 (2004).
118. Folkman, M. J., O'Reilly, M. S., Cao, Y., Sim, K.L.: US20030064926A1 (2003).
119. O'Reilly, M.S., Folkman, M.J., Cao, Y.: US20010029246A1 (2001).
120. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
121. Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, - 9, and -13. J Biol Chem 2003; 278(25): 22404-22411.
122. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27872-27879.
123. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-16469.
124. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-11726.
125. Urbich C, Reissner A, Chavakis E, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the antiangiogenic effects of endostatin. FASEB J 2002; 16: 706-708.
126. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
127. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-251.
128. Maatta M, Heljasvaara R, Pihlajaniemi T, et al. Collagen XVIII/ endostatin shows a ubiquitous distribution in human ocular tissues and endostatin-containing fragments accumulate in ocular fluid samples. Graefes Arch Clin Exp Ophthalmol 2007; 245(1): 74-81.
129. Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci 2007; 14(3): 313-322.
130. Niu XG, Wang W, Shi WY, et al. Inhibition of corneal neovascularization by liposomes mediated plasmid encoding human endostatin. Zhonghua Yan Ke Za Zhi 2005; 41(3): 260-264.
131. Zhang P, Wu D, Ge J, et al. Experimental inhibition of corneal neovascularization by endostatin gene transfection in vivo. Chin Med J 2003; 116(12): 1869-1874.
132. Folkman, J., Javaherian, K., Robert, T.T.: US20060251699A1 (2006).
133. Folkman, M.J., O'Reilly, M.: US20050282253A1 (2005).
134. O'Reilly, M., Folkman, M. J.: US20020123458A1 (2002).
135. Wilson SE, He YG, Lloyd SA. EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci 1992; 33(5): 1756-1765.
136. Shams NB, Sigel MM, Davis RM. Interferon-gamma, Staphylococcus aureus, and lipopolysaccharides/silica enhance interleukin-1 beta production by human corneal cells. Reg Immunol 1989; 2: 136-148.
137. Sakamoto S, Inada K, Chiba K, et al. Production of IL-6 and IL-1a by human corneal epithelial cells. Acta Soc Ophthalmol Jpn 1991; 95: 728-732.
138. Sakamoto S, Inada K. Human corneal epithelial, stromal and endothelial cells produce interleukin-6. Acta Soc Ophthalmol Jpn1992; 96: 702-709.
139. Cubitt CL, Lausch RN, Oakes JE. Differences in interleukin-6 gene expression between cultured human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci 1995; 36: 330-336.
140. Cubitt CL, Tang Q, Monteiro CA, et al. IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci 1993; 34: 3199-3206.
141. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007; 105: 330-343.
142. Hong JW, Liu JJ, Lee JS, et al. Proinflammatory chemokine induction in keratocytes and inflammatory cell infiltration into the cornea. Invest Ophthalmol Vis Sci 2001; 42: 2795-2803.
143. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-κB, in treatment of corneal alkali burns in mice. Am J Pathol 2005; 166: 1393-1403.
144. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1β-induced corneal neovascularization role of nuclear factor-κB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007; 171(3): 1058-1065.
145. Eigler A, Sinha B, Hartmann G, et al. strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-492.
146. Henricson BE, Benjamin WR, Vogel SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990; 58: 2429-2437.
147. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-4023.
148. Niederkorn JY, Peeler JS, Mellon J. Phagocytosis of particulate antigens by corneal epithelial cells stimulates interleukin-1 secretion and migration of Langerhans cells into the central cornea. Reg Immunol 1989; 2: 83-90.
149. Staats HF, Lausch RN. Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy. J Immunol 1993; 151: 277-283.
150. Elner VM, Strieter RM, Pavilack MA, et al. Human corneal interleukin-8 IL-1 and TNF-induced gene expression and secretion. Am J Pathol 1991; 139: 977-988.
151. Dekaris I, Zhu SN, Dana MR. TNF-alpha regulates corneal Langerhans cell migration. J Immunol1999; 162: 4235-4239.
152. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, et al. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol 2007; 52: 3-19.
153. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor. Science 1986; 232(4755): 1250-1253.
154. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000; 19(4): 526-533.
155. Pepper MS. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8(1): 21-43.
156. Sakamoto T, Ueno H, Sonoda K, et al. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Ther 2000; 7(22): 1915-1924.
157. Pasquale LR, Dorman-Pease ME, Lutty GA, et al. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 1993; 34(1): 23-30.
158. Nishida K, Kinoshita S, Yokoi N, et al. Immunohistochemical localization of transforming growth factor-beta 1, -beta 2, and -beta 3 latency-associated peptide in human cornea. Invest Ophthalmol Vis Sci 1994; 35(8): 3289-3294.
159. Joyce NC, Zieske JD. Transforming growth factor-beta receptor expression in human cornea. Invest Ophthalmol Vis Sci 1997; 38(10): 1922-1928.
160. Hayashi K, Frangieh G, Wolf G, et al. Expression of transforming growth factor-beta in wound healing of vitamin A-deficient rat corneas. Invest Ophthalmol Vis Sci 1989; 30: 239-247.
161. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factorbeta in fibroblastic and epithelial cells. J Biol Chem 1994; 269(9): 6271-6274.
162. Baer JC, Foster CS. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology 1992; 99(2): 173-179.
163. Nirankari VS, Baer JC. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology 1986; 93: 1304-1309.
164. Ahmad N, Mukhtar H. Mechanism of photodynamic therapyinduced cell death. Methods Enzymol 2000; 319: 342-358.
165. Sheppard Jr, Epstein RJ, Lattanzio Jr, et al. Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether. Am J Ophthalmol 2006; 141(3): 524-529.
166. Yoon KC, You IC, Kang IS, et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol 2007; 144(3): 390-395.
167. Clark, A.F.: US6297228B1 (1999).
168. BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997; 38: 1954-1962.
169. Phillips K, Arffa R, Cintron C, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983; 101: 640-643.
170. Planck SR, Rich LF, Ansel JC, et al. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocul Immunol Inflamm 1997; 5(2): 95-100.
171. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 1989; 30(7): 1588-1593.
172. Pleyer U, Dannowski H, Volk HD, et al. Corneal allograft rejection: Current understanding. I. Immunobiology and basic mechanisms. Ophthalmologica 2001; 215(4): 254-262.
173. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341(2-3): 309-315.
174. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230(4732): 1375-1378.
175. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112(1): 139-143.
176. Jonas J, Heatley G, Spaide R, et al. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 2005; 14(2): 168-171.
177. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87(4): 462-468.
178. Clark, A. F.: US5770592A (1998).
179. Clark, A. F., Conrow R. E.: EP1236471A2 (2002).
180. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 2007; 52: S26-34.
181. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19 -27.
182. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983; 172: 214-218.
183. Harada S, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 1994; 93: 2490-2496.
184. Pakneshan P, Birsner AE, Adini I, et al. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 2008; 49(9): 3909-3913.
185. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423.
186. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
187. Amico C, Yakimov M, Catania MV, et al. Differential expression of cyclooxygenase-1 and cyclooxygenase-2 in the cornea during wound healing. Tissue Cell 2004; 36(1): 1-12.
188. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26(1): 25-35.
189. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
190. Bock F, König Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246(2): 281-284.
191. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (avastin) for corneal neovascularization - corneal light shield soaked application. Cornea 2009; 28(2): 246-247.
192. You IC, Kang IS, Lee SH, et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2008; 87(6): 653-658.
193. Han YS, Lee JE, Jung JW, et al. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247(4): 541-548.
194. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007; 35(8): 745-748.
195. Qian CX, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27(9): 1090-1092.
196. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008; 27(6): 743-745.
197. D'amato, R.J., Green, S.J., Swartz Jr., G. M., Shah, J.H., Madsen, J.: US20050004087A1 (2005).
198. D'amato, R.: US6071948 (2000).
199. Benelli U, Bocci G, Danesi R, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res 1998; 67: 133-142.
200. Joussen AM, Germann T, Kirchhof B. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefes Arch Clin Exp Ophthalmol 1999; 237(12): 952-961.
201. Bocci G, Danesi R, Benelli U, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999; 43: 205-212.
202. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993; 90: 2690-2694.
203. Wu PC, Liu CC, Chen C, et al. Inhibition of experimental angiogenesis of cornea by somatostatin. Graefe's Arch Clin Exp Ophthalmol 2003; 241: 63-69.
204. Demir T, Celiker UO, Kukner A, et al. Effect of Octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 1999; 77: 386-390.
205. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 1998; 236: 785-789.
206. Joussen AM, Kruse FE: Topical application of methotrexate for inhibition of corneal angiogenesis. Graefe's Arch Clin Exp Ophthalmol 1999; 237: 920-927.
207. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005; 46: 454-460.
208. Sloper CM, Powell RJ, Dua HS. Tacrolimus in the management of high risk corneal and limbal grafts. Ophthalmology 2001; 108: 1838-1844.